aTYR PHARMA (ATYR) Common Equity (2014 - 2026)

aTYR PHARMA (ATYR) has reported Common Equity for 13 consecutive years, with $48.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity fell 34.65% year-over-year to $48.8 million; the trailing twelve-month figure through Jun 2026 stood at $48.8 million (down 34.65% YoY), and the FY2025 full-year result was $67.5 million, down 3.37% from the prior year.
• Common Equity fell to $48.8 million in Q2 2026 per ATYR's latest filing, from $57.7 million in the prior quarter.
• Across five years, Common Equity topped out at $109.7 million in Q1 2023 and bottomed at $48.8 million in Q2 2026.
• Historically, Common Equity has averaged $80.1 million across 5 years, with a median of $78.6 million in 2022.
• The widest YoY moves for Common Equity: up 111.88% in 2022, down 34.68% in 2022.
• Over 5 years, Common Equity stood at $71.3 million in 2022, then climbed by 26.91% to $90.5 million in 2023, then dropped by 22.81% to $69.8 million in 2024, then dropped by 3.37% to $67.5 million in 2025, then retreated by 27.7% to $48.8 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $48.8 million, $57.7 million, and $67.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.